Zai Lab Ltd.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Zai Lab Ltd.
Novo gets worldwide development and commercial rights except for Heartseed’s home market in Japan. LianBio unveils licensing partnerships with Lyra, Landos and Nanobiotix.
The launch of efgartigimod at the end of 2021 is very much Argenx's focus now that J&J is terminating their alliance for the anti-CD70 antibody cusatuzumab for acute myeloid leukemia "in consideration of the evolving standard of care" for the disease.
Hot on the heels of a high-profile US approval, Chinese biotechs from BeiGene, Betta to Zai Lab and lesser-known InventisBio, are racing to get their KRAS-targeting cancer drugs launched. Zai Lab, however, hopes to win with a potential best-in-class contender from its partner Mirati of the US.
Public Company Edition: The Nasdaq Biotechnology Index appears to be in recovery from an earlier slide, but still has ground to make up. Also, Jazz sold $1.5bn worth of notes and Zai Lab closed an $823.9m follow-on offering.
- Other Names / Subsidiaries
- Zai Lab Limited
- Zai Lab (Shanghai) Co., Ltd.